Metabolic reprogramming of tumor cells in the TME promotes the expression of L-glutamine transporters ASCT2(SLC1A5) and SN2(SLC38A5), alongside glutamic acid–metabolizing enzymes (e.g., glutaminase [GLS]), glutamine synthetase, and aminotransferases, thereby increasing L-glutamine intake. The gene discussed is GLS; the disease is neoplasm.